Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

Keizer, Bart de; Aken, Maarten O. van; Feelders, Richard A; Herder, Wouter W. de; Kam, Boen L.R.; Essen, Marc van; Krenning, Eric P.; Kwekkeboom, Dik J.

doi:10.1007/s00259-007-0691-z

Cited by 106 publications

(68 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prolonged or (re-)hospitalisation after therapy because of probably PRRT-induced hormonal crises occurred in six (1%) patients (de Keizer et al 2008). All patients recovered after adequate care including fluid infusion, high-dose i.v.…”

Section: Lu-labelled Somatostatin Analoguesmentioning

confidence: 99%

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours

Teunissen¹,

Kwekkeboom²,

Valkema³

et al. 2011

Endocrine-Related Cancer

104

View full text Add to dashboard Cite

Nuclear medicine plays a pivotal role in the imaging and treatment of neuroendocrine tumours (NETs). Somatostatin receptor scintigraphy (SRS) with [ 111 ]octreotide has proven its role in the diagnosis and staging of gastroenteropancreatic NETs (GEP-NETs). New techniques in somatostatin receptor imaging include the use of different radiolabelled somatostatin analogues with higher affinity and different affinity profiles to the somatostatin receptor subtypes. Most of these analogues can also be labelled with positron-emitting radionuclides that are being used in positron emission tomography imaging. The latter imaging modality, especially in the combination with computed tomography, is of interest because of encouraging results in terms of improved imaging quality and detection capabilities. Considerable advances have been made in the imaging of NETs, but to find the ideal imaging method with increased sensitivity and better topographic localisation of the primary and metastatic disease remains the ultimate goal of research. This review provides an overview of the currently used imaging modalities and ongoing developments in the imaging of NETs, with the emphasis on nuclear medicine and puts them in perspective of clinical practice. The advantage of SRS over other imaging modalities in GEP-NETs is that it can be used to select patients with sufficient uptake for treatment with radiolabelled somatostatin analogues. Peptide receptor radionuclide therapy (PRRT) is a promising new tool in the management of patients with inoperable or metastasised NETs as it can induce symptomatic improvement with all Indium-111, ]octreotate, a survival benefit of several years compared with historical controls has been reported.

show abstract

Section: Lu-labelled Somatostatin Analoguesmentioning

confidence: 99%

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours

Teunissen¹,

Kwekkeboom²,

Valkema³

et al. 2011

Endocrine-Related Cancer

104

View full text Add to dashboard Cite

show abstract

“…Safford et al also reported two deaths from myocardial infarction following high dose 131 I-MIBG therapy with a dose of 300 mCi (11.1 GBq) [22]. However, a 177 Lu-DOTATATE treatment-induced catecholamine crisis in a pheochromocytoma or paraganglioma patient has been described in only one case of malignant pheochromocytoma, in which the patient developed hypotension, excessive sweating and cardiac ischemia 1 day after 177 Lu-DOTATATE therapy [23]. The patient was pre-treated with corticosteroids for subsequent treatments; however, the authors did not provide further details.…”

mentioning

confidence: 99%

The Challenges of Treating Paraganglioma Patients with 177Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment Protocols

Makis¹,

McCann²,

McEwan³

2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose A high percentage of paragangliomas express somatostatin receptors that can be utilized for targeted radioisotope therapy. The aim of this study was to describe and discuss the challenges of treating these tumors with 177 Lu-[DOTA 0 ,Tyr 3 ]octreotate (DOTATATE) radioisotope therapy using established protocols. Methods and Results Three paraganglioma patients were treated with 4-5 cycles of 177

show abstract

“…(Ahlman et al, 1987;Marsh et al, 1987;Roy et al, 1987;Ahlman et al, 1988a;Ockert and White, 1988;Darby et al, 1990;Debas and Mulvihill, 1994;Deguchi et al, 1994;Parry et al, 1996;Pekarek et al, 1997;Balestrero et al, 2000;Janssen et al, 2000;Kharrat and Taubin, 2003;Zimmer et al, 2003;Koopmans et al, 2005;Davi et al, 2006;Majeed et al, 2007;Papadogias et al, 2007;De Keizer et al, 2008;McPherson et al, 2009;Sinha et al, 2009;Yazbek-Karam et al, 2009;Fujie et al, 2010;Morrisroe et al, 2012;Raikhelkar et al, 2012;Shah et al, 2012;Massimino et al, 2013;van Diepen et al, 2013) The prophylactic usage of SSTA was diverse between different studies varying from long acting SSTA to continuous somatostatin infusion. Of the 28 patients with known demographic information, 17 cases (60.7%) were men and 11 cases (39.3%) were women.…”

Section: Resultsmentioning

confidence: 99%

Somatostatin Analogues Do Not Prevent Carcinoid Crisis

Guo

Tang²

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Carcinoid crisis is a life-threating syndrome of neuroendocrine tumors (NETs) characterized by dramatic blood pressure fluctuation, arrhythmias, and bronchospasm. In the era of booming anti-tumor therapeutics, this has become more important since associated stresses can trigger carcinoid crisis. Somatostatin analogues (SSTA) have been recommended for prophylactic administration before intervention procedures for functioning NETs. However, the efficacy is still controversial. The aim of this article is to review efficacy of SSTA for preventing carcinoid crisis. Materials and Methods: PubMed, Cochrane Controlled trials Register, and EMBASE were searched using 'carcinoid crisis' as a search term combining terms with 'somatostatin'; 'octreotide'; 'lanreotide' and 'pasireotide' until December 2013. Results: Twenty-eight articles were retrieved with a total of fifty-three unique patients identified for carcinoid crisis. The most common primary sites of NETs were the small intestine and respiratory tract. The triggering factors for carcinoid crisis included anesthesia/ surgery (63.5%), interventional therapy (11.5%), radionuclide therapy (9.6%), examination (7.7%), medication (3.8%), biopsy (2%) and spontaneous (2%). No randomized controlled trials (RCTs) were identified and two case-control studies were included to assess the efficacy of SSTA for preventing carcinoid crisis by meta-analysis. The overall pooled risk of perioperative carcinoid crisis was similar despite the prophylactic administration of SSTA (OR 0.44, 95% CI: 0.14 to 1.35, p=0.15). Conclusions: SSTA wasnot helpful for preventing carcinoid crisis based on a meta-analysis of retrospective studies. Attentive monitoring and careful intervention are essential. Future studies with better quality are needed to clarify any effect of SSTA for preventing carcinoid crisis.

show abstract

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

Cited by 106 publications

References 22 publications

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours

The Challenges of Treating Paraganglioma Patients with 177Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment Protocols

Somatostatin Analogues Do Not Prevent Carcinoid Crisis

Contact Info

Product

Resources

About